US 12,012,618 B2
Engineered galactose oxidase variant enzymes
Christopher Michael Micklitsch, Philadelphia, PA (US); Oscar Alvizo, Fremont, CA (US); Jovana Nazor, Milpitas, CA (US); Harvinder Chagger Maniar, Hayward, CA (US); Mikayla Jianghongxia Krawczyk, Palo Alto, CA (US); Margie Tabuga Borra-Garske, Palo Alto, CA (US); Nandhitha Subramanian, Cambridge (GB); Anna Fryszkowska, New York, NY (US); Nicholas M. Marshall, Rahway, NJ (US); Agustina Rodriguez-Granillo, Rahway, NJ (US); Deeptak Verma, Rahway, NJ (US); and Dewan Andrews, Rahway, NJ (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Sep. 9, 2022, as Appl. No. 17/931,003.
Application 17/931,003 is a division of application No. 16/460,376, filed on Jul. 2, 2019, granted, now 11,466,259.
Claims priority of provisional application 62/822,286, filed on Mar. 22, 2019.
Claims priority of provisional application 62/695,570, filed on Jul. 9, 2018.
Prior Publication US 2023/0026007 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/04 (2006.01); C12N 15/52 (2006.01); C12N 9/02 (2006.01); C12P 21/02 (2006.01)
CPC C12N 9/0006 (2013.01) [C12N 15/52 (2013.01); C12N 9/001 (2013.01); C12P 21/02 (2013.01); C12Y 101/03009 (2013.01)] 15 Claims
 
1. An engineered galactose oxidase comprising a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 1912, or a functional fragment thereof, wherein said engineered galactose oxidase comprises substitutions as compared to SEQ ID NO: 1912 in said polypeptide sequence at positions 291, 375, 453, and 465, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1912.